Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hybutimibe + atorvastatin vs ezetimibe + atorvastatin in metabolic syndrome with ischemic stroke
ChiCTR2600117066Phase 4Recruiting
- Sponsor
- Shenzhen Second People's Hospital
- Start
- Jan 2026
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of hybutimibe, ezetimibe and atorvastatin in cardiometabolic risk (CMR), ischemic stroke, hypercholesterolemia and 1 more (2 arms), sponsored by Shenzhen Second People's Hospital. Primary endpoints: Percentage change in LDL-C from baseline to week 12, Incidence of major adverse cardiovascular events (MACE) within 12 weeks and 1 more. Started Jan 2026; status: recruiting.
02
Drugs
hybutimibeezetimibeatorvastatin
03
Conditions
cardiometabolic risk (CMR)ischemic strokehypercholesterolemiadyslipidemia
Beyond the preview
Go deeper on ChiCTR2600117066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600117066.